Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kanglaogujin is a traditional Chinese medicine formulation, most commonly referenced as "kanglaogujin particles." It is used in China as an adjunctive therapy, particularly in the context of anti-tuberculosis treatment. The product appears to be administered orally and is studied for its potential to mitigate drug-induced side effects or enhance efficacy when combined with standard anti-tuberculosis drugs. Its precise mechanism of action is not well characterized in Western pharmacological terms, but it likely involves modulation of immune response or support of organ function during prolonged drug therapy[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kanglaogujin.